|
tyyppi |
julkaisu |
| 3 |
Lehti |
Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212. |
| 13 |
Lehti |
Stiles ML, Allen LV.
Stability of nafcillin sodium, oxacillin sodium, penicillin G potassium, penicillin G sodium and tobramycin sulfate in polyvinyl chloride drug reservoirs.
Am J Health-Syst Pharm 1997 ; 54: 1068-1070. |
| 19 |
Lehti |
Bell RG, Lipford LC, Massanari MJ, Riley CM.
Stability of intravenous admixtures of aztreonam and cefoxitin, gentamicin, metronidazole, or tobramycin.
Am J Hosp Pharm 1986 ; 43: 1444-1453. |
| 59 |
Lehti |
Trissel LA, Gilbert DL, Martinez JF, Kim MC.
Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2192-2196. |
| 63 |
Lehti |
Marquardt Ed, Lam SSY.
Visual compatibility of fentanyl citrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 811-812. |
| 73 |
Lehti |
Lor E, Takagi J.
Visual compatibility of foscarnet with other injectable drugs.
Am J Hosp Pharm 1990 ; 47: 157-159. |
| 84 |
Lehti |
Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499. |
| 99 |
Lehti |
Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090. |
| 104 |
Lehti |
Hall PD, Yui D, Lyons S, Bosso JA.
Compatibility of filgrastim with selected antimicrobial drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 185-189. |
| 129 |
Lehti |
Smythe M, Malouf E.
Visual compatibility of insulin with secondary intravenous drugs in admixtures.
Am J Hosp Pharm 1991 ; 48: 125-126. |
| 169 |
Lehti |
Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363. |
| 176 |
Lehti |
Mantong ML, Marquardt ED.
Visual compatibility of midazolam hydrochloride with selected drugs during simulated Y-site injection.
Am J Health-Syst Pharm 1995 ; 52: 2567-2568. |
| 182 |
Lehti |
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60. |
| 198 |
Lehti |
Gayed AA, Kheshary PR, Hinkle RL.
Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection.
Am J Health-Syst Pharm 1995 ; 52: 516-520. |
| 244 |
Lehti |
Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913. |
| 249 |
Lehti |
Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045. |
| 251 |
Lehti |
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713. |
| 253 |
Lehti |
Trissel LA, Chandler SW, Folstad JT.
Visual compatibility of amsacrine with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1990 ; 47: 2525-2528. |
| 285 |
Lehti |
Elmore RL, Contois ME, Kelly J, Noe A, Poirier A.
Stability and compatibility of admixtures of intravenous ciprofloxacin and selected drugs.
Clin Ther 1996 ; 18: 246-255. |
| 299 |
Lehti |
Trissel LA, Martinez JF, Gilbert DL.
Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1735-1741. |
| 300 |
Lehti |
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292. |
| 301 |
Lehti |
Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.
Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1295-1300. |
| 307 |
Lehti |
Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799. |
| 316 |
Lehti |
Veltri M, Lee CKK.
Compatibility of neonatal parenteral nutrient solutions with selected intravenous drugs.
Am J Health-Syst Pharm 1996 ; 53: 2611-2613. |
| 317 |
Lehti |
Kershaw BP, Monnier HL, Mason JH.
Visual compatibility of premixed theophylline or heparin with selected drugs for IV administration.
Am J Hosp Pharm 1993 ; 50: 1360-1362. |
| 335 |
Lehti |
Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406. |
| 336 |
Lehti |
Forman JK, Lachs JR, Souney PF.
Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection.
Am J Hosp Pharm 1987 ; 44: 1408-1409. |
| 337 |
Lehti |
Bashaw ED, Amantea MA, Minor JR, Galleli JF.
Visual compatibility of zidovudine with other drugs during simulated Y-site administration.
Am J Hosp Pharm 1988 ; 45: 2532-2533. |
| 367 |
Lehti |
Thompson DF, Allen LV, Desai SR, Rao PS.
Compatibility of furosemide with aminoglycoside admixtures.
Am J Hosp Pharm 1985 ; 42: 116-119. |
| 384 |
Lehti |
Colucci RD, Cobuzzi LE, Halpern NA.
Visual compatibility of esmolol hydrochloride and various injectable drugs during simulated Y-site injection.
Am J Hosp Pharm 1988 ; 45: 630-632. |
| 385 |
Lehti |
Benedict MK, Roche VF, Banakar UV, Hilleman DE.
Visual compatibility of amiodarone hydrochloride with various antimicrobial agents during simulated Y-site injection.
Am J Hosp Pharm 1988 ; 45: 1117-1118. |
| 386 |
Lehti |
Colucci RD, Cobuzzi LE, Halpern NA.
Visual compatibility of labetalol hydrochloride injection with various injectable drugs during simulated Y-site injection.
Am J Hosp Pharm 1988 ; 45: 1357-1358. |
| 405 |
Lehti |
Nieves-Cordero AL, Luciw HM, Souney PF.
Compatibility of narcotic analgesic solutions with various antibiotics during simulated Y-site injection.
Am J Hosp Pharm 1985 ; 42: 1108-1109. |
| 406 |
Lehti |
Smythe MA, Patel MA, Gasloli RA.
Visual compatibility of narcotic analgesics with selected intravenous admixtures.
Am J Hosp Pharm 1990 ; 47: 819-820. |
| 434 |
Lehti |
Goodwin SD, Nix DE, Heyd A, Wilton JH.
Compatibility of ciprofloxacin injection with selected drugs and solutions.
Am J Hosp Pharm 1991 ; 48: 2166-2171. |
| 472 |
Lehti |
Wohlford JG, Fowler MD.
Visual compatibility of hetastarch with injectable critical-care drugs.
Am J Hosp Pharm 1989 ; 46: 995-996. |
| 479 |
Lehti |
Min DI, Brown T, HWang GC.
Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 2964-2966. |
| 492 |
Lehti |
Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189. |
| 494 |
Lehti |
Thompson DF, Heflin NR.
Incompatibility of injectable indomethacin with gentamicin sulfate or tobramycin sulfate.
Am J Hosp Pharm 1992 ; 49: 836,838. |
| 496 |
Lehti |
Lor E, Sheybani T, Takagi J.
Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration.
Am J Hosp Pharm 1991 ; 48: 744-746. |
| 500 |
Lehti |
Tucker DR, Sieradzan R.
Visual compatibility of ciprofloxacin lactate with five broad-spectrum antimicrobial agents during simulated Y-site injection.
Am J Hosp Pharm 1988 ; 45: 1910-1911. |
| 503 |
Lehti |
Nahata MC, Durrell DE.
Stability of tobramycin sulfate in admixtures with calcium gluconate.
Am J Hosp Pharm 1985 ; 45: 1987-1988. |
| 565 |
Lehti |
Marble DA, Bosso JA, Townsend RJ.
Compatibility of clindamycin phosphate with amikacin sulfate at room temperature and with gentamicin sulfate and tobramycin sulfate under frozen conditions.
Drug Intell Clin Pharm 1986 ; 20: 960-963. |
| 575 |
Lehti |
Holmes CJ, Ausman RK, Kundsin RB, Walter CW.
Effect of freezing and microwave thawing on the stability of six antibiotic admixtures in plastic bags.
Am J Hosp Pharm 1982 ; 39: 104-108. |
| 604 |
Laboratorio |
Stabilité des médicaments dans l'Intermate® SV50, 100, 200
Baxter 1998 |
| 612 |
Lehti |
Frable RA, Klink PR, Engel GL, Mundell EE.
Stability of cefamandole nafate injection with parenteral solutions and additives.
Am J Hosp Pharm 1982 ; 39: 622-627. |
| 639 |
Lehti |
Zbrozek AS, Marble DA, Bosso JA, Bair JN, Townsend RJ.
Compatibility and stability of clindamycin phosphate - aminoglycoside combinations within polypropylene syringes.
Drug Intell Clin Pharm 1987 ; 21: 806-810. |
| 660 |
Lehti |
Michaels MR, Stauffer GL, Haas DP.
Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility.
Ann Pharmacotherapy 1996 ; 30: 228-232. |
| 673 |
Lehti |
Bullock L, Clark JH, Fitzgerald JF, Glick MR, Hancock BG, Baenziger JC, Black CD.
The stability of amikacin, gentamicin, and tobramycin in total nutrient admixtures.
JPEN 1989 ; 13: 505-509. |
| 709 |
Lehti |
Seitz DJ, Archambault JR, Brinck-Johnsen T.
Stability of tobramycin sulfate in plastic syringes.
Am J Hosp Pharm 1980 ; 37: 1614-1615. |
| 889 |
Lehti |
Janknegt R, Stratermans T, Cilissen J, Lohman JJHM, Hooymans PM.
Ofloxacin intravenous. Compatibility with other antibacterial agents.
Pharm Weekbl [Sci] 1991 ; 13: 207-209. |
| 905 |
Lehti |
Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017. |
| 921 |
Lehti |
Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292. |
| 999 |
Lehti |
Watson D.
Piggyback compatibility of antibiotics with pediatric parenteral nutrition solution.
JPEN 1985 ; 9: 220-224. |
| 1035 |
Lehti |
Bisaillon S, Sarrazin R.
Compatibility of several antibiotics or hydrocortisone when added to metronidazole solution for intravenous infusion.
J Parenter Sci Technol 1983 ; 37: 129-132. |
| 1047 |
Lehti |
Souney PF, Colucci RD, Mariani G, Campbell D.
Compatibility of magnesium sulfate solutions with various antibiotics during simulated Y-site injection.
Am J Hosp Pharm 1984 ; 41: 323-324. |
| 1057 |
Lehti |
Cutie MR.
Compatibility of verapamil hydrochloride injection with commonly used additives.
Am J Hosp Pharm 1983 ; 40: 1205-1207. |
| 1168 |
Lehti |
Konishi H, Goto M, Nakamoto Y, Yamamoto I, Yamashina H.
Tobramycin inactivation by carbenicillin, ticarcillin and piperacillin.
Antimicrob Agents Chemother 1983 ; 23: 653-657. |
| 1206 |
Lehti |
Frear RS.
Cefoperazone-aminoglycoside incompatibility.
Am J Hosp Pharm 1983 ; 40: 564. |
| 1232 |
Lehti |
Beatson C, Taylor A.
A physical compatibility study of furosemide & flucloxacillin injections.
Br J Pharm Pract 1987 ; 9: 223-226, 236. |
| 1315 |
Lehti |
Halpern NA, Colucci RD, Alicea M, Greenstein R.
Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection.
Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297. |
| 1410 |
Lehti |
Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145. |
| 1415 |
Lehti |
Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.
Compatibility of medications with 3-in-1 parenteral nutrition admixtures.
JPEN 1999 ; 23: 67-74. |
| 1423 |
Lehti |
Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518. |
| 1490 |
Lehti |
Halpern NA, Colucci RD, Alicea M, Greenstein R.
The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection.
Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254. |
| 1611 |
Lehti |
Chalmers JR, Bobek MB, Militello MA.
Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs.
Am J Health-Syst Pharm 2001 ; 58: 504-506. |
| 1625 |
Lehti |
Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321. |
| 1704 |
Lehti |
Xu QA, Trissel LA, Saenz A.
Stability of gentamicin sulfate and tobramycin sulfate in autodose infusion system bags.
Int J Pharm Compound 2002 ; 6: 152-154. |
| 1712 |
Lehti |
Trissel LA, Saenz CA.
Compatibility screening of Precedex during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 230-233. |
| 1713 |
Lehti |
Trissel LA, Saenz CA.
Compatibility screening of bivalirudin during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 311-315. |
| 1721 |
Lehti |
Trissel LA, Williams KY, Baker MB.
Compatibility screening of Hextend during simulated Y-site administration with other drugs.
Int J Pharm Compound 2001 ; 5: 69-72. |
| 1745 |
Lehti |
Thompson DF, Heflin NR.
Incompatibility of injectable indomethacin with gentamicin sulfate or tobramycin sulfate.
Am J Health-Syst Pharm 1992 ; 49: 836-838. |
| 1754 |
Lehti |
Trissel LA, Gilbert DL, Wolkin AC.
Compatibility of docetaxel with selected drugs during simulated Y-site administration.
Int J Pharm Compound 1999 ; 3: 241-244. |
| 1759 |
Lehti |
Servais H, Tulkens PM.
Stability and compatibility of ceftazidime administered by continuous infusion to intensive care patients.
Antimicrob Agents Chemother 2001 ; 45: 2643-2647. |
| 1800 |
Lehti |
Voytilla KL, Tyler LS, Rusho WJ.
Visual compatibility of azithromycin with 24 commonly used drugs during simulated Y-site delivery.
Am J Health-Syst Pharm 2002 ; 59: 853-855. |
| 1803 |
Lehti |
Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB.
Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2003 ; 60: 80-85. |
| 1925 |
Lehti |
Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519. |
| 1953 |
Lehti |
Trissel LA, Saenz CA, Ogundele AB, Ingram DS.
Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2004 ; 61: 2289-2293. |
| 1982 |
Lehti |
Trissel LA, Ogundele AB.
Compatibility of anidulafungin with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2005 ; 62: 834-837. |
| 2087 |
Lehti |
Ferreira E, Forest JM, Hildgen P.
Compatibility of dimenhydrinate injectable by Y administration.
Pharmactuel 2004 ; 37: 17-20. |
| 2090 |
Lehti |
Pere H, Chasse V, Forest JM, Hildgen P.
Compatibility of injectable pantoprazole in Y-site administration.
Pharmactuel 2004 ; 37: 193-196. |
| 2109 |
Lehti |
Pelletier E, Forest JM, Hildgen P.
Compatibilité de la kétamine injectable lors de l’administration en dérivé avec d’autres médicaments usuels.
Pharmactuel 2006 ; 39: 71-75. |
| 2141 |
Lehti |
Barinian N, Chanteux H, Viaene E, Servais H, Tulkens PM.
Stability and compatibility study of cefepime in comparaison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units.
J Antimicrob Chemother 2003 ; 51: 651-658. |
| 2231 |
Lehti |
de Jongh R, Hens R, Basma V, mouton JW, Tulkens PM, Carryn S.
Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection.
J Antimicrob Chemother 2008 ; 61, 2: 382-388. |
| 2247 |
Lehti |
Chan P, Heatherly K, Kupiec T.C, Trissel L.A.
Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2008 ; 12, 3: 276-278. |
| 2262 |
Lehti |
Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D.
Compatibility of doripenem with other drugs during simulated Y-site administratioN
Am J Health-Syst Pharm 2008 ; 65: 1261-1265. |
| 2269 |
Lehti |
Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H.
Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551. |
| 2296 |
Laboratorio |
Témocilline (Negaban®) - Résumé des caractéristiques du produit
Eumedica 2017 |
| 2353 |
Lehti |
Xu Q.A, Trissel L.A, Zhang Y, Williams K.Y.
Compatibility and stability of linezolid injection admixted with gentamicin sulfate and tobramycin sulfate.
Int J Pharm Compound 2000 ; 4, 6: 476-479. |
| 2369 |
Lehti |
Mason NA, Johnson CE, O'Brien MA.
Stability of ceftazidime and tobramycin sulfate in peritoneal dialysis solution
Am J Hosp Pharm 1992 ; 49: 1139 - 1142. |
| 3012 |
Lehti |
Sullivan T, Forrest J.M, Leclair G.
Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration
Hosp Pharm 2015 ; 50, 3: 214-220. |
| 3122 |
Lehti |
Dotson B, Lynn S, Savakis K, Churchwell MD.
Physical compatibility of 4% sodium citrate with selected antimicrobial agents.
Am J Health-Syst Pharm 2010 ; 67: 1195-1198. |
| 3152 |
Lehti |
Kumar A, Mann HJ.
Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2010 ; 67: 1640-1644. |
| 3201 |
Lehti |
Dice JE.
Physical compatibility of alprostadil with commonly used IV solutions and medications in the neonatal intensive care unit.
J Pediatr Pharmacol Ther 2006 ; 11:233?6. |
| 3216 |
Lehti |
Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G.
Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y.
Pharmactuel 2011 ; 44, 1 : 14-18 |
| 3249 |
Lehti |
Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB.
Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2011 ; 68: 2163-2169. |
| 3254 |
Lehti |
Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L.
Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration
Am J Health-Syst Pharm 2011 ; 68: 2265-2270. |
| 3332 |
Laboratorio |
Tigecycline (Tigacyl®) - Summary of Product characteristics
Pfizer 2012 |
| 3385 |
Lehti |
Raverdi V, Ampe E, Hecq JD, Tulkens PM.
Stability and compatibility of vancomycin for administration by continuous infusion.
J Antimicrob Chemother 2013 ; 68: 1179-1182. |
| 3408 |
Lehti |
Tollec S, Touzin K, Pelletier E, Forest J.M.
Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels.
Pharmactuel 2013 ; 46, 1 : 16-21. |
| 3522 |
Laboratorio |
Flucloxacillin - Summary of Product Characteristics.
Actavis 2013 |
| 3523 |
Laboratorio |
Ceftriaxone (Rocephin®) - Summary of Product Characteristics.
Roche 2018 |
| 3526 |
Laboratorio |
Clindamycin (Dalacin®) - Summary of Product Characteristics
Pharmacia 2010 |
| 3527 |
Laboratorio |
Amoxicillin (Amoxil®) – Summary of Product Characteristics
Glaxo Smith Kline 2018 |
| 3540 |
Laboratorio |
Heparin sodium - Summary of Product Characteristics.
Wockhardt 2010 |
| 3543 |
Laboratorio |
Ceftazidime – Summary of Product Characteristics
Wockhardt 2013 |
| 3544 |
Laboratorio |
Cefoperazone (Cefobid®) - Summary of Product Characteristics
Pfizer 2006 |
| 3545 |
Laboratorio |
Amoxicilline / acide clavulanique - Résumé des caractéristiques du produit
Mylan SAS 2009 |
| 3546 |
Laboratorio |
Cefamandole Flavelab - Résumé des caractéristiques du produit
Panpharma SA 2007 |
| 3548 |
Laboratorio |
Cefepime (Maxipime®) - Summary of Product caracteristics.
Bristol Myers Squibb 2007 |
| 3578 |
Laboratorio |
Cisplatin - Summary of Product Characteristics
Accord Healthcare 2011 |
| 3586 |
Laboratorio |
Piperacilline tazobactam Actavis® - Résumé des caractéristiques du produit
Actavis France 2010 |
| 3587 |
Laboratorio |
Ticarcilline/acide clavulanique (Timentin®) - Summary of Product Characteristics
GlaxoSmithKline 2014 |
| 3594 |
Laboratorio |
Metronidazole (Flagyl®) - Summary of Product Characteristics
Zentiva 2013 |
| 3644 |
Laboratorio |
Calcium gluconate® - Summary of Product Characteristics
Hameln Pharmaceuticals 2010 |
| 3656 |
Laboratorio |
Teicoplanine (Targocid®) - Résumé des caractéristiques du produit
Sanofi Aventis France 2014 |
| 3674 |
Laboratorio |
Erythromycin lactobionate - Summary of Product Characteristics
PanPharma 2016 |
| 3677 |
Laboratorio |
Cefpirome (Cefrom®) - Résumé des caractéristiques du produit
Sanofi Aventis France 2008 |
| 3687 |
Laboratorio |
Cefuroxime sodium - Summary of Product Characteristics
Stravencon 2013 |
| 3728 |
Lehti |
Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B.
Visual compatibility of defibrotide with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2014 ; 71: 1288-1291. |
| 3767 |
Lehti |
Legris M.E, Lavoie A, Forrest J.M, Hildgen P.
Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels.
Pharmactuel 2014 ; 47, 3 : 167-172. |
| 3824 |
Lehti |
Boudi S, Roy H, Forest JM, Leclair G.
Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y.
Pharmactuel 2023 2023;56,3:91-98 |
| 3827 |
ilmoitus |
Ghazi I.M, Hamada Y, Nicolau D.P.
Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions.
ASHP Midyear 2015 |
| 3828 |
ilmoitus |
Thabit A.K, Hamada Y, Nicolau D.P.
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
ASHP Midyear 2015 |
| 3829 |
ilmoitus |
So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015 |
| 3883 |
Laboratorio |
Ceftazidime - Résumé des caractéristiques du produit
Arrow 2016 |
| 3964 |
Lehti |
Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G.
Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments.
Pharmactuel 2017 ; 50,1 : 27-33. |
| 4055 |
Lehti |
Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 , 75, 1:36-44 |
| 4319 |
Lehti |
Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G.
Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs.
Hosp Pharm 2020 ; 55, 5: 332-337. |
| 4389 |
Lehti |
Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G.
Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosimendan et la kétamine.
Pharmactuel 2019 ;52,4:206-213 |
| 4434 |
Lehti |
Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L.
Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration.
Clin Ther 2019 ; 41, 10: 2162-2170. |
| 4445 |
Lehti |
Reed M.D, Perry E.B, Fennell S.J, Brissie E.O, Ball W.D.
Antibiotic compatibility and stability in a parenteral nutrition solution.
Chemotherapy 1979 ; 25: 336-345. |
| 4528 |
Lehti |
Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N.
Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.
Int J Pharm Compound 2021 ;25,1:52-61 |
| 4603 |
Lehti |
Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G.
Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration.
Hosp Pharm 2021 ; 56, 4: 228-234. |
| 4650 |
Laboratorio |
Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021.
Advanz Pharma 2021 |
| 4742 |
Lehti |
Macoviciuc M, Nguyen C, Forest J-M, Leclair G.
Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y.
Pharmactuel 2022 ; 55, 4: 247-255. |
| 4801 |
Lehti |
Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J.
Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2024 ;51,1: |
